Paul R Carter

Address:

10412 13 Ave Ct E, Tacoma, WA 98445

Phone:

2535380530

VIN:

3GSDL43N69S593610

Make:

SATURN

Model:

VUE

Year:

2009

US Patent:

7638606, Dec 29, 2009

Filed:

Nov 4, 2004

Appl. No.:

10/578410

Inventors:

Paul J. Carter - Mercer Island WA, US
Hongxing Zhou - Bellevue WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

C07K 16/28

US Classification:

53038815, 5303882, 4241421, 4241431

Abstract:

The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

US Patent:

7872113, Jan 18, 2011

Filed:

Aug 4, 2009

Appl. No.:

12/535648

Inventors:

Paul J. Carter - Mercer Island WA, US
Hongxing Zhou - Bellevue WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

C07H 21/04

US Classification:

536 2353, 536 243

Abstract:

The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

US Patent:

8067546, Nov 29, 2011

Filed:

Apr 19, 2006

Appl. No.:

11/912096

Inventors:

Charlotte McDonagh - Seattle WA, US
Paul Carter - Mercer Island WA, US
Julie McEarchern - Mill Creek WA, US

Assignee:

Seattle Genetics, Inc. - Bothell WA

International Classification:

C12P 21/08
C07K 16/00
C07K 17/00
C07K 17/14
A61K 39/00
A61K 39/395

US Classification:

5303873, 5303881, 53038823, 5303911, 5303917, 4241331, 4241411, 4241781, 4241831

Abstract:

Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.

US Patent:

8562987, Oct 22, 2013

Filed:

Oct 11, 2011

Appl. No.:

13/271143

Inventors:

Charlotte McDonagh - Winchster MA, US
Paul Carter - Mercer Island WA, US
Julie McEarchern - Mill Creek WA, US

Assignee:

Seattle Genetics, Inc. - Bothell WA

International Classification:

A61K 39/00

US Classification:

4241331, 4241781

Abstract:

Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.

US Patent:

20040052793, Mar 18, 2004

Filed:

Aug 2, 2002

Appl. No.:

10/182975

Inventors:

Paul Carter - Mercer Island WA, US
Lewis Gazzard - Skipton North, GB

International Classification:

A61K039/395

US Classification:

424/146100, 424/178100

Abstract:

The invention provides novel methods for the localized delivery of pharmaceutical agents by the administration of a caspase conjugate that targets a cell type of interest and the additional administration of a pro-agent that is locally converted, in the presence of the caspase, to an active agent. The invention further provides novel tageting agents comprising a caspase as well as novel prodrugs comprising a caspase cleavable prodrug moiety. The invention also provides pharmaceutical compositions as well as methods of treatment comprising the caspase conjugates and prodrugs of the invention

US Patent:

20050112694, May 26, 2005

Filed:

Nov 4, 2004

Appl. No.:

10/982359

Inventors:

Paul Carter - Mercer Island WA, US
Hongxing Zhou - Bellevue WA, US

International Classification:

G01N033/53
C12P021/04
C07K016/28

US Classification:

435007100, 530388220

Abstract:

The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.

US Patent:

20070104719, May 10, 2007

Filed:

Sep 29, 2006

Appl. No.:

11/537578

Inventors:

Paul Carter - Mercer Island WA, US
Lewis Gazzard - North Yorkshire, GB

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39/395

US Classification:

424155100, 424178100

Abstract:

The invention provides novel method for the localized delivery of pharmaceutical agents by the administration of a caspase conjugate that targets a cell type of interest and the additional administration of a pro-agent that is locally converted, in the presence of the caspase, to an active agent. The invention further provides novel tageting agents comprising a caspase as well as novel prodrugs comprising a caspase cleavable prodrug moiety. The invention also provides pharmaceutical compositions as well as methods of treatment comprising the caspase conjugates and prodrugs of the invention

US Patent:

20080124765, May 29, 2008

Filed:

Nov 21, 2007

Appl. No.:

11/944406

Inventors:

Paul J. CARTER - Mercer Island WA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12P 21/04
C07K 16/18

US Classification:

435 696, 5303871

Abstract:

Methods for the high yield production of antibody Fv-containing polypeptides, especially Fab′ and F(ab′)antibody fragments are provided. Expression of heavy and light chain Fv in a microbial secretory system is followed by recovery of Fv from the periplasm under conditions that maintain a cysteine residue as a free thiol. The free thiol is reacted with free thiol of an antibody fragment of the same or differing specificity, or with agents such as diagnostic labels or therapeutic moieties. The products offer advantages of homogeneity and purity not available through the use of known methods for preparing such derivatives.